Lima José Lacet, Dias-Ribeiro Eduardo, Ferreira-Rocha Julierme, Soares Ramon, Costa Fábio Wildson Gurgel, Fan Song, Sant'ana Eduardo
Residency Program of Oral Maxillofacial Surgery, Dental Association of Paraíba; Surgeon, Department of Oral Maxillofacial Surgery, State Emergency and Trauma Hospital, João Pessoa, PB, Brazil.
Anesth Prog. 2013 Summer;60(2):42-5. doi: 10.2344/0003-3006-60.2.42.
We compared the buccal infiltration of 4% articaine with 1 : 100,000 or 1 : 200,000 epinephrine without a palatal injection for the extraction of impacted maxillary third molars with chronic pericoronitis. This prospective, double-blind, controlled clinical trial involved 30 patients between the ages of 15 and 46 years who desired extraction of a partially impacted upper third molar with pericoronitis. Group 1 (15 patients) received 4% articaine with 1 : 100,000 epinephrine and group 2 (15 patients) received 4% articaine with 1 : 200,000 epinephrine by buccal infiltration. None of the patients in group 1 reported pain, but 3 patients in group 2 reported pain, which indicated a need for a supplementary palatal injection. The palatal injections were all successful in eliminating the pain. Two additional patients in group 2 experienced pain when the suture needle penetrated their palatal mucosa. Based on these results, 4% articaine with 1 : 100,000 epinephrine was found to be more effective for the removal of upper third molars in the presence of pericoronitis than 4% articaine hydrochloride with 1 : 200,000 epinephrine when only a buccal infiltration was used.
我们比较了在不拔腭侧注射的情况下,使用含1∶100,000或1∶200,000肾上腺素的4%阿替卡因进行颊侧浸润麻醉,用于拔除患有慢性冠周炎的上颌第三磨牙的效果。这项前瞻性、双盲、对照临床试验纳入了30例年龄在15至46岁之间、希望拔除部分阻生且患有冠周炎的上颌第三磨牙的患者。第1组(15例患者)接受含1∶100,000肾上腺素的4%阿替卡因,第2组(15例患者)通过颊侧浸润接受含1∶200,000肾上腺素的4%阿替卡因。第1组患者均未报告疼痛,但第2组有3例患者报告疼痛,这表明需要补充腭侧注射。腭侧注射均成功消除了疼痛。第2组另有2例患者在缝线针穿透腭黏膜时感到疼痛。基于这些结果,发现在仅使用颊侧浸润麻醉时,含1∶100,000肾上腺素的4%阿替卡因在拔除患有冠周炎的上颌第三磨牙方面比含1∶200,000肾上腺素的4%盐酸阿替卡因更有效。